BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peng H. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Antib Ther 2021;4:222-7. [PMID: 34805745 DOI: 10.1093/abt/tbab023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Peng H, Nerreter T, Mestermann K, Wachter J, Chang J, Hudecek M, Rader C. ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene 2022. [PMID: 35859167 DOI: 10.1038/s41388-022-02416-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Yan Q, Fang X, Li C, Lan P, Guan X. Oncofetal proteins and cancer stem cells. Essays in Biochemistry 2022. [DOI: 10.1042/ebc20220025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sheyi R, de la Torre BG, Albericio F. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics 2022;14:396. [DOI: 10.3390/pharmaceutics14020396] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]